Skip to main content

Year: 2023

Correction to Aktia Bank Plc:s Interim report January-September 2023

Aktia Bank Plc Stock Exchange Release 9 November 2023 at 12.35 p.m. Correction to Aktia Bank Plc:s Interim report January-September 2023 Aktia Bank Plc:s Interim report was not included as an appendix in the stock exchange release regarding the Interim report January-September 2023, which was published by Aktia Bank Plc earlier today. The entire Interim Report is attached to this release. AKTIA BANK PLC For more information: Outi Henriksson, CFO, tel. +358 10 247 6236 ir@aktia.fi Distribution: Nasdaq Helsinki Ltd Central media www.aktia.com Aktia is a Finnish asset manager, bank and life insurer that has been creating wealth and wellbeing from one generation to the next for 200 years. We serve our customers in digital channels everywhere and face-to-face in our offices in the Helsinki, Turku, Tampere, Vaasa and Oulu regions. Our award-winning...

Continue reading

Himax Technologies, Inc. Reports Third Quarter 2023 Financial Results; Provides Fourth Quarter 2023 Guidance

Q3 2023 Revenues and EPS Beat Guidance, Gross Margin at Upper End of Guidance Range Issued on August 10, 2023 Company Q4 2023 Guidance: Revenues to Decline 5.0% to 11.0% QoQ, Gross Margin is Expected to be around 30%, Profit per diluted ADS to be around 9.0 Cents to 13.0 CentsQ3 2023 revenues were $238.5M, an increase of 1.5% QoQ, exceeding the guidance range of a 7.0% decline to flat QoQ. Q3 GM reached 31.4%, substantially improving from the Q2 trough, a result of strategic termination of certain high-cost foundry capacity agreements in Q2. Q3 GM surpassed guidance range of 30.5% to 32.0%, due to a favorable product mix, primarily driven by the remarkable performance of automotive product line Q3 2023 after-tax profit was $11.2M, or 6.4 cents per diluted ADS, compared to $0.9M, or 0.5 cents last quarter Company’s Q4 2023 revenues to...

Continue reading

Genmab to Present at Jefferies London Healthcare Conference

Media Release COPENHAGEN, Denmark; November 9, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony Pagano will take part in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2023 at 11:00 AM CET / 5:00 AM EST. A webcast of the event will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data...

Continue reading

Form 8.3 – Kin and Carta Plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Jupiter Fund Management Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Kin & Carta plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date dealing undertaken:        For an opening position disclosure,...

Continue reading

Form 8.3 – [Picton Property Income Limited – Opening Disclosure – 08 11 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree PICTON PROPERTY INCOME LIMITED(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Nexans empowers the UK’s energy transition connecting Orkney Islands to Scottish Mainland

Nexans empowers the UK’s energy transition connecting Orkney Islands to Scottish Mainland _PRESS RELEASE_Nexans has signed a capacity reservation agreement with Scottish transmission owner SSEN Transmission to supply and install approximately 100 km of 220 kV high-voltage cables, both onshore and offshore. These cables will provide a transmission connection from Orkney to the Scottish mainland at Dounreay on the north coast of Scotland. The Orkney Islands represent a major source of renewable electricity potential, and its connection to the mainland will help decarbonize the UK’s electricity production.Paris, November 9, 2023 – Nexans, a leader in the design and manufacturing of cable systems and services, announces that it has been selected by SSEN Transmission to supply and install the high-voltage cables that...

Continue reading

Share Buyback Transaction Details November 2 – November 8, 2023

Share Buyback Transaction Details November 2 – November 8, 2023 November 9, 2023 – Wolters Kluwer (Euronext: WKL), a global leading provider of expert solutions, insights and services for professionals, today reports that it has repurchased 249,733 of its own ordinary shares in the period from November 2, 2023, up to and including November 8, 2023, for €29.5 million and at an average share price of €118.04. These repurchases are part of the share buyback program announced on February 22, 2023, under which we intend to repurchase shares for up to €1 billion during 2023. The cumulative amounts repurchased to date under this year’s buyback program are as follows: Share Buyback 2023Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2023 to date 7,426,100...

Continue reading

Li Auto Inc. Announces Unaudited Third Quarter 2023 Financial Results

Quarterly total revenues reached RMB34.68 billion (US$4.75 billion)1Quarterly deliveries reached 105,108 vehicles BEIJING, China, Nov. 09, 2023 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced its unaudited financial results for the quarter ended September 30, 2023. Operating Highlights for the Third Quarter of 2023Total vehicle deliveries were 105,108 units in the third quarter of 2023, representing a 296.3% year-over-year increase.Deliveries   2023 Q3   2023 Q2   2023 Q1   2022 Q4    105,108   86,533   52,584   46,319                 Deliveries   2022 Q3   2022 Q2   2022 Q1   2021 Q4    26,524   28,687   31,716   35,221As of September 30, 2023, the Company had 361 retail stores covering 131 cities, as well...

Continue reading

Mendus AB Interim Report January – September 2023

Press Release Stockholm, Sweden, November 9, 2023So far in 2023, Mendus has realized significant progress in its corporate development, and we aim to end the year strong The progress made in the previous quarters provided the basis for a financing round which we completed in July, to support the next stage of our corporate development. The directed placement and rights issue totaling SEK 317M supports further read-outs of the ongoing ADVANCE II and ALISON vididencel trials, the start of new clinical trials with vididencel and ilixadencel and progressing our preclinical pipeline. Additionally, Mendus has entered into a manufacturing alliance with NorthX Biologics, to support large-scale manufacturing of its lead product candidate vididencel. The regulatory status of vididencel was strengthened in Q3 by the Fast Track Designation granted...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.